Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

Background/AimsInfliximab (IFX) often loses its therapeutic effect in initial responders with inflammatory bowel disease (IBD) over time. Low serum IFX trough levels (TLs) are linked to poor clinical response and outcomes. Maintenance of optimal therapeutic IFX concentrations is important for sustai...

Повний опис

Бібліографічні деталі
Автори:	So Yoon Choi, Ben Kang, Yon Ho Choe
Формат:	Стаття
Мова:	English
Опубліковано:	Gastroenterology Council for Gut and Liver 2019-09-01
Серія:	Gut and Liver
Предмети:	infliximab drug monitoring pediatric inflammatory bowel disease
Онлайн доступ:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl18129

Схожі ресурси

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
за авторством: So Yoon Choi, та інші
Опубліковано: (2017-01-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
за авторством: Yiyoung Kwon, та інші
Опубліковано: (2022-09-01)

High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease
за авторством: Isaac Rodin, та інші
Опубліковано: (2020-06-01)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
за авторством: So Yoon Choi, та інші
Опубліковано: (2023-06-01)

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
за авторством: Gyeol Seong, та інші
Опубліковано: (2020-06-01)

Inflammatory bowel disease of the lung: The role of infliximab?
за авторством: Adam J. Hayek, та інші
Опубліковано: (2015-01-01)

Early infliximab antibody testing does not prevent infusion reactions when reinitiating infliximab
за авторством: Joseph D. Feuerstein
Опубліковано: (2016-08-01)

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
за авторством: Yoo Min Lee, та інші
Опубліковано: (2024-05-01)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
за авторством: Jennifer C. C. deBruyn, та інші
Опубліковано: (2021-07-01)

Safety profile and side effects of infliximab and adalimumab in inflammatory bowel disease at a referral center in northeastern Brazil
за авторством: Joelma Aurélio de Sousa Santos, та інші
Опубліковано: (2024-02-01)

Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study
за авторством: Ryan S. Funk, та інші
Опубліковано: (2021-05-01)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
за авторством: Sujin Choi, та інші
Опубліковано: (2021-07-01)

Antitumor necrosis factor treatment for pediatric inflammatory bowel disease
за авторством: Darja Urlep, та інші
Опубліковано: (2013-10-01)

Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
за авторством: Douglas Zabrowski, та інші
Опубліковано: (2020-08-01)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
за авторством: Jaeyoung Choi, та інші
Опубліковано: (2018-05-01)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
за авторством: Wan Chee Ong, та інші
Опубліковано: (2022-07-01)

Remission of Cap Polyposis Maintained for More Than Three Years after Infliximab Treatment
Опубліковано: (2009-12-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
за авторством: Ivaylo Vazharov, та інші
Опубліковано: (2016-12-01)

Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
за авторством: Han Wang, та інші
Опубліковано: (2022-11-01)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
за авторством: van der Maas Aatke, та інші
Опубліковано: (2012-09-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
за авторством: Manuel Sutter, та інші
Опубліковано: (2021-08-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
за авторством: Kouzhu Zhu, та інші
Опубліковано: (2024-08-01)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
за авторством: Eirini Theodoraki, та інші
Опубліковано: (2021-10-01)

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
за авторством: Youlian Zhou, та інші
Опубліковано: (2018-02-01)

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
за авторством: Youlian Zhou, та інші
Опубліковано: (2018-02-01)

Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
за авторством: Susana Clemente Bautista, та інші
Опубліковано: (2024-12-01)

Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
за авторством: Paula Zapata-Cobo, та інші
Опубліковано: (2023-10-01)

Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
за авторством: Othman Alharbi, та інші
Опубліковано: (2023-01-01)

HOW IS THE DIET QUALITY OF PATIENTS WITH CROHN’S DISEASE IN CLINICAL REMISSION USING INFLIXIMAB?
за авторством: Melissa Mercadante Santana CRUZ, та інші
Опубліковано: (2021-10-01)

Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
за авторством: Bokyeong Lee, та інші
Опубліковано: (2024-10-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
за авторством: Aibar Aginbay, та інші
Опубліковано: (2022-11-01)

Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context
за авторством: Zvonimir Petric, та інші
Опубліковано: (2024-09-01)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
за авторством: Aze Wilson, та інші
Опубліковано: (2021-02-01)

The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
за авторством: Junya Song, та інші
Опубліковано: (2024-12-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
за авторством: Subedi S, та інші
Опубліковано: (2019-07-01)

Uso de infliximabe na policondrite recidivante Infliximab in relapsing polychondritis
за авторством: Ana Paula Soares de Barros, та інші
Опубліковано: (2010-04-01)

Anthocyanins from purple corn affect gut microbiota and metabolome in inflammatory bowel disease patients under infliximab infusion: the SiCURA pilot study
за авторством: Mirco Vacca, та інші
Опубліковано: (2024-11-01)

Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis
за авторством: Rachid Kaddoura, та інші
Опубліковано: (2023-03-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
за авторством: Hye-In Jung, та інші
Опубліковано: (2021-01-01)

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
за авторством: Bahez Gareb, та інші
Опубліковано: (2019-08-01)